Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. DOPTELET represents the first thrombopoietin receptor agonist approved in the US for this indication.
Our first meeting
An introduction from a friend of PBM team led to the discovery of an asset buried within a large pharma’s portfolio. PBM team recognized the drug candidate’s inadequate fit to Eisai’s strategic focus and understood the unmet need for the patients with chronic liver disease. In March 2016, PBM Capital acquired avatrombopag to build Dova and operated the company, including overseeing clinical trials, finance, regulatory and manufacturing until we brought on a management team on before the IPO. Paul and Sean are currently serving on the Board of Directors.